Finance

Lists
TARS:NASDAQ
Tarsus Pharmaceuticals Inc
$69.12
+1.54%
(+1.05) 1D
Oct 19, 11:12:04 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TARS...
Open
$68.08
High
$69.45
Low
$68.08
Mkt. cap
3.38B
Avg. vol.
944.80K
Volume
86.63K
52-wk high
$91.53
52-wk low
$53.89
EPS
-$1.08
Beta
0.44
Shares outstanding
46.79M
No. of employees
370
Open
$68.08
High
$69.45
Low
$68.08
Mkt. cap
3.38B
Avg. vol.
944.80K
Volume
86.63K
52-wk high
$91.53
52-wk low
$53.89
EPS
-$1.08
Beta
0.44
Shares outstanding
46.79M
No. of employees
370
News stories
From web sources and news partners
About Tarsus Pharmaceuticals Inc
CEO-
Employees370
Founded2016
HeadquartersIrvine, California, United States
SectorPharmaceutical industry
Websitetarsusrx.com
Analyst ratings
Based on 10 analysts giving stock ratings to TARS in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for TARS in the last 3 months.
Highest
Current $69.12
$116.00 (+67.82%)
Average
$99.56 (+44.04%)
Lowest
$84.00 (+21.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
$84.00
+21.5%
10/12/2026
Jenna Davidner
Barclays
Buy
Reiterated
$110.00
+59.1%
10/09/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
$100.00
+44.7%
10/02/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
$116.00
+67.8%
09/24/2026
Dennis Ding
Jefferies
Buy
Reiterated
$105.00
+51.9%
09/08/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/12/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$100.00
+44.7%
08/11/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$104.00
+50.5%
08/08/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$88.00
+27.3%
08/07/2026
Eddie Hickman
Guggenheim
Buy
Maintained
$89.00
+28.8%
07/21/2026
Andreas Argyrides
Chardan Capital
Buy
Maintained
$98.00
+41.8%
04/24/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
-$0.43 / -$0.20
-119.39%miss
Revenue / Est. (USD)
173.91M / 169.51M
+2.59%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
118.70M
151.67M
162.05M
173.91M
Cost of goods sold
24.59M
28.96M
31.75M
12.11M
Cost of revenue
24.59M
28.96M
31.75M
12.11M
Research and development expenses
-
-
-
31.01M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
108.63M
130.68M
136.43M
150.70M
Operating expense
108.63M
130.68M
136.43M
181.71M
Total operating expenses
133.23M
159.64M
168.18M
193.82M
Operating income
-14.53M
-7.98M
-6.12M
-19.91M
Other non operating income
98.00K
4.48M
-936.00K
-281.00K
EBT including unusual items
-12.58M
-6.31M
-4.62M
-15.84M
EBT excluding unusual items
-12.58M
-1.76M
-5.46M
-18.65M
Income tax expense
-
2.06M
2.35M
2.72M
Effective tax rate
-
-32.61%
-50.96%
-17.15%
Other operating expenses
-
-
-
-
Net income
-12.58M
-8.37M
-6.97M
-18.55M
Net profit margin
-10.60%
-5.52%
-4.30%
-10.67%
Earnings per share
-0.30
-0.20
-0.16
-0.43
Interest and investment income
4.11M
3.95M
3.72M
3.70M
Interest expense
-2.27M
-2.21M
-2.13M
-2.16M
Net interest expenses
1.85M
1.74M
1.59M
1.54M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.07M
-7.53M
-5.68M
-18.91M
Gain or loss from assets sale
-
-
-
183.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps